Partnering

APG101

Apogenix wishes to establish a strategic partnership with a fully committed partner for late-stage clinical development and commercialisation of its lead product, APG101, on a worldwide basis.
APG101 has been proven to be safe and well tolerated in preclinical and clinical trials. The substance is produced in a high-yield, proprietary production process which allows for the production of, e.g., phase III material. The company has built a comprehensive patent portfolio protecting APG101 until 2024 and beyond. With its most advanced drug candidate, Apogenix is targeting commercially attractive indications with high unmet medical needs. APG101 is currently being developed for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndrome (MDS).
In December 2009, a clinical phase II trial for the treatment of GBM was initiated. Enrolment was completed in September 2011 and final results regarding the primary study endpoint will be available in Q1/2012. It is planned to begin with an additional phase II trial in MDS next year.
Non-confidential information as well as preclinical and clinical data are available upon request.

APG350

Apogenix wishes to establish a partnership with a fully committed partner for clinical development and commercialisation of its TRAIL receptor agonist programme on a worldwide basis.  
The TRAIL pathway has been shown to play an important role in many solid and hematopoietic cancers. There is a sound scientific rationale for the use of TRAIL receptor agonists especially in indications where new treatment options are much needed such as, e.g., lung and colon cancer, non-Hodgkin´s lymphoma, and multiple myeloma.
Apogenix has engineered novel TRAIL receptor agonists with improved efficacy and enhanced pharmacokinetic parameters to address this very attractive market. The fully human fusion proteins have been constructed to induce multimerisation of TRAIL receptors, thereby triggering apoptosis of established cancer cell lines, primary tumour cells and cancer stem cells at a much higher rate than other compounds. This has been shown not only in vitro but also in a number of in vivo tumour models.
In summary, Apogenix´ TRAIL receptor agonists are attractive candidates for future clinical development. Non-confidential information as well as preclinical and safety/tox data are available upon request.